On Oct. 5, 2006, the Foundation for the National Institutes of Health, NIH, FDA, and the Pharmaceutical Research and Manufacturers of America, a public-private biomedical research partnership, formed The Biomarkers Consortium to search for and validate new biomarkers to accelerate the delivery of new technologies, medicines, and therapies for prevention, early detection, diagnosis, and treatment of disease. The first projects, to be undertaken by National Cancer Institute, will be two clinical trials, one in non-Hodgkin lymphoma and one in lung cancer.